Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3)

NCT00394589 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

43

Enrollment

INDUSTRY

Sponsor class

Stopped Study enrollment was stopped due to insufficient subject accrual.

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Infliximab Increased Frequency
DRUG: Infliximab Increased Dose
DRUG: Infliximab Control

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]